{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:07:07Z","timestamp":1784718427087,"version":"3.55.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejps.2025.107193","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:38:10Z","timestamp":1751942290000},"page":"107193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies"],"prefix":"10.1016","volume":"212","author":[{"given":"Naixiong","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9489-0627","authenticated-orcid":false,"given":"Changchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107193_bib0001","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0002","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101543","article-title":"Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines","volume":"26","author":"Abramenkovs","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107193_bib0005","series-title":"Dual Inhibition of PARP and ATR Induces Homologous Recombination Repair Deficiency and Leads to Synthetic Lethality in Prostate Cancer With CDK12 Alteration","author":"Akamatsu","year":"2023"},{"key":"10.1016\/j.ejps.2025.107193_bib0006","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0007","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0009","series-title":"A Phase Ib\/II Study of Intermittent Talazoparib Plus Temozolomide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and No Mutations in DNA Damage Repair (DDR)","author":"Autio","year":"2023"},{"key":"10.1016\/j.ejps.2025.107193_bib0010","author":"Azad","year":"2025"},{"key":"10.1016\/j.ejps.2025.107193_bib0011","series-title":"PETRANHA: Phase 1\/2 Study of AZD5305+ Novel Hormonal Agents in Patients With Metastatic Prostate Cancer\u2013Interim Safety and Pharmacokinetic Results","author":"Azad","year":"2024"},{"key":"10.1016\/j.ejps.2025.107193_bib0012","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0013","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.09207","article-title":"SPOP mutation leads to genomic instability in prostate cancer","volume":"4","author":"Boysen","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.ejps.2025.107193_bib0014","first-page":"726","article-title":"Interfocal genomic heterogeneity uncovered","volume":"15","author":"Bradley","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0015","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejps.2025.107193_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-025-00841-4","article-title":"Mechanisms and regulation of DNA end resection in the maintenance of genome stability","author":"Ceccaldi","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejps.2025.107193_bib0017","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-024-07909-9","article-title":"Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection","volume":"634","author":"Ceppi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0019","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","article-title":"Significance of BRCA2 and RB1 Co-loss in aggressive prostate cancer progression","volume":"26","author":"Chakraborty","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0020","article-title":"Analysis of BRCA germline mutations in Chinese prostate cancer patients","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial","author":"Chi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0023","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0024","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0025","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107193_bib0027","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","article-title":"TRIP13 regulates DNA repair pathway choice through REV7 conformational change","volume":"22","author":"Clairmont","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejps.2025.107193_bib0028","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ejps.2025.107193_bib0029","series-title":"Final Overall Survival (OS) in PROpel: Abiraterone (abi) and Olaparib (ola) Versus Abiraterone and Placebo (pbo) as First-Line (1L) Therapy For Metastatic Castration-Resistant Prostate Cancer (mCRPC)","author":"Clarke","year":"2023"},{"key":"10.1016\/j.ejps.2025.107193_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-024-00991-8","article-title":"Prostate cancer epigenetics - from pathophysiology to clinical application","author":"Constancio","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0031","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0032","series-title":"KEYNOTE-199: Pembrolizumab (pembro) for Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC)","author":"De Bono","year":"2018"},{"key":"10.1016\/j.ejps.2025.107193_bib0033","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1038\/s41467-022-32756-5","article-title":"The KU-PARP14 axis differentially regulates DNA resection at stalled replication forks by MRE11 and EXO1","volume":"13","author":"Dhoonmoon","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0034","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0035","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/nm1016-1192c","article-title":"Corrigendum: blocking c-met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0037","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molcel.2017.06.023","article-title":"RADX promotes genome stability and modulates chemosensitivity by regulating RAD51 at replication forks","volume":"67","author":"Dungrawala","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0038","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with Abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0039","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JU.0000000000001363","article-title":"Comparative analysis of genomic alterations across castration sensitive and castration resistant prostate cancer via circulating tumor DNA sequencing","volume":"205","author":"Fan","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0041","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejps.2025.107193_bib0042","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(25)00031-2","volume":"26","author":"Fay","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0043","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0044","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0046","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","author":"Garje","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0047","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241258443","article-title":"Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?","volume":"16","author":"Garofoli","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17053","article-title":"Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): a systematic review and single-arm meta-analysis","volume":"42","author":"Gazzoni","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0049","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"NPJ. Precis. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-med-082523-083843","article-title":"New therapeutic options for BRCA mutant patients","volume":"76","author":"Ghanem","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0051","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2019.05.012","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"35","author":"Gogola","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0052","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1073\/pnas.1908547116","article-title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","volume":"116","author":"Gui","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2025.107193_bib0053","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1101\/gad.256214.114","article-title":"Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4","volume":"29","author":"Guillemette","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejps.2025.107193_bib0054","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0055","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0056","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","article-title":"DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells","volume":"563","author":"He","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0057","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, Olaparib, or Abiraterone + Olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0058","series-title":"BRCAAWAY: A randomized Phase 2 Trial of abiraterone, olaparib, Or abiraterone+ Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With DNA Repair Defects","author":"Hussain","year":"2022"},{"key":"10.1016\/j.ejps.2025.107193_bib0059","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0060","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41388-022-02427-2","article-title":"A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer","volume":"41","author":"Ipsen","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejps.2025.107193_bib0061","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0062","series-title":"Combination of PDL-1 and PARP Inhibition in an Unselected Population With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)","author":"Karzai","year":"2017"},{"key":"10.1016\/j.ejps.2025.107193_bib0063","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0064","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","article-title":"Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts","volume":"9","author":"Kolesnichenko","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2025.107193_bib0065","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0066","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2025.107193_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"12","author":"Kwan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0068","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0069","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \"BRCAness\" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejps.2025.107193_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103824","article-title":"Targeting dePARylation in cancer therapy","volume":"148","author":"Li","year":"2025","journal-title":"DNA Repair."},{"key":"10.1016\/j.ejps.2025.107193_bib0072","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2025.107193_bib0073","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2025.107193_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116288","article-title":"The power and the promise of synthetic lethality for clinical application in cancer treatment","volume":"172","author":"Liu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107193_bib0075","article-title":"FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition","volume":"43","author":"Liu","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejps.2025.107193_bib0076","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with Rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0077","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.tranon.2019.04.007","article-title":"Overexpressed ABCB1 induces olaparib-taxane cross-resistance in advanced prostate cancer","volume":"12","author":"Lombard","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0078","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejps.2025.107193_bib0079","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41467-023-37499-5","article-title":"TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to Olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0081","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102726","article-title":"First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: applying clinical study findings to clinical practice in the United States","volume":"126","author":"McKay","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2025.107193_bib0083","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0084","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","article-title":"Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics","volume":"78","author":"Nguyen","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0086","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2023.11.014","article-title":"Co-occurring BRCA2\/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer","volume":"7","author":"Orme","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0087","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2025.107193_bib0088","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41467-019-09232-8","article-title":"The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors","volume":"10","author":"Peng","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0089","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0090","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.molcel.2021.04.028","article-title":"Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease","volume":"81","author":"Prokhorova","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030801","article-title":"Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now?","volume":"14","author":"Rao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107193_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.09.003","article-title":"Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer and BRCA1\/2 gene alterations: final analysis from the randomized phase 3 MAGNITUDE trial","author":"Rathkopf","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0093","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2413954121","article-title":"PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer","volume":"121","author":"Ravindranathan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2025.107193_bib0094","article-title":"Results from a phase 2 study of induction Docetaxel and carboplatin followed by maintenance Rucaparib in the treatment of patients with metastatic castration-resistant prostate cancer with DNA homologous recombination repair deficiency","author":"Raychaudhuri","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0095","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejps.2025.107193_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.01.002","article-title":"Association of prior PARP inhibitor exposure with clinical outcomes after (177)Lu-PSMA-617 in men with castration-resistant prostate cancer and mutations in DNA homologous recombination repair genes","author":"Raychaudhuri","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0097","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0098","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.adt3034","article-title":"CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade","volume":"388","author":"Rogers","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ejps.2025.107193_bib0099","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejps.2025.107193_bib0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094712","article-title":"Immune checkpoint inhibitors: a promising treatment option for metastatic castration-resistant prostate cancer?","volume":"22","author":"Ruiz de Porras","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107193_bib0101","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","article-title":"Tolerability of Olaparib combined with Abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 PROpel trial","volume":"7","author":"Saad","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0102","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41586-024-07910-2","article-title":"Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination","volume":"634","author":"Salunkhe","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107193_bib0103","series-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","author":"Sandhu","year":"2023"},{"key":"10.1016\/j.ejps.2025.107193_bib0104","doi-asserted-by":"crossref","first-page":"26795","DOI":"10.1073\/pnas.2008830117","article-title":"p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase","volume":"117","author":"Sarangi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2025.107193_bib0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41419-024-06949-3","article-title":"Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer","volume":"15","author":"Sarwar","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejps.2025.107193_bib0106","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-Mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0107","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107193_bib0108","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0109","series-title":"Therapeutic Implications of Homologous Repair Deficiency Testing in Patients With Prostate Cancer (Part 2 of 2)","author":"Serritella","year":"2024"},{"key":"10.1016\/j.ejps.2025.107193_bib0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of Immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0111","series-title":"Homologous Recombination Repair Gene Mutation (HRRm) Testing Patterns and Treatment Selection from a Real-World Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","author":"Shore","year":"2024"},{"key":"10.1016\/j.ejps.2025.107193_bib0112","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejps.2025.107193_bib0113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12885-020-6657-2","article-title":"Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report","volume":"20","author":"Simmons","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0114","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1038\/s41467-024-48629-y","article-title":"Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis","volume":"15","author":"Singhal","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pros.24454","article-title":"Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer","volume":"83","author":"Su","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.ejps.2025.107193_bib0116","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41594-023-01074-9","article-title":"Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs","volume":"30","author":"Swift","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejps.2025.107193_bib0117","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","article-title":"Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-Family fork remodelers","volume":"68","author":"Taglialatela","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0118","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41589-024-01611-7","article-title":"UFL1 triggers replication fork degradation by MRE11 in BRCA1\/2-deficient cells","volume":"20","author":"Tian","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejps.2025.107193_bib0119","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molcel.2015.12.013","article-title":"HELB is a feedback inhibitor of DNA end resection","volume":"61","author":"Tkac","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0121","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0122","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107193_bib0124","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-024-00526-9","article-title":"Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy","volume":"8","author":"Walmsley","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117955","article-title":"Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: implications for precision medicine","volume":"185","author":"Wang","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107193_bib0126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0127","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2019.06.004","article-title":"Germline DNA repair gene mutation landscape in Chinese prostate cancer patients","volume":"76","author":"Wei","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bju.16462","article-title":"Impact of homologous recombination repair\/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer","volume":"135","author":"Wenzel","year":"2025","journal-title":"BJU Int."},{"key":"10.1016\/j.ejps.2025.107193_bib0129","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s43018-024-00902-1","article-title":"Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability","volume":"6","author":"Whalen","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-020-14657-7","article-title":"A case report of multiple primary prostate tumors with differential drug sensitivity","volume":"11","author":"Wilkinson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0131","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.33324","article-title":"Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients","volume":"148","author":"Wu","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107193_bib0132","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2025.107193_bib0133","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","article-title":"Olaparib combined with Abiraterone versus Olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after Abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study","volume":"7","author":"Xie","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0134","doi-asserted-by":"crossref","unstructured":"Yap, T.A., Im, S.-A., Schram, A.M., Sharp, A., Balmana, J., Baird, R.D., Brown, J.S., Schwaederle, M., Pilling, E.A., Moorthy, G., 2022. Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations.","DOI":"10.1158\/1538-7445.AM2022-CT007"},{"key":"10.1016\/j.ejps.2025.107193_bib0135","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","article-title":"Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","volume":"72","author":"Ying","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107193_bib0136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus Olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort a study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107193_bib0137","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107193_bib0138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322689121","article-title":"Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions","volume":"121","author":"Zentout","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2025.107193_bib0139","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186871","article-title":"SPOP mutations increase PARP inhibitor sensitivity via CK2\/PIAS1\/SPOP axis in prostate cancer","volume":"10","author":"Zhang","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejps.2025.107193_bib0140","first-page":"159","article-title":"Recent development and future prospects of molecular targeted therapy in prostate cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107193_bib0141","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-024-47664-z","article-title":"High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107193_bib0142","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12967-025-06486-3","article-title":"Advances in tumor subclone formation and mechanisms of growth and invasion","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejps.2025.107193_bib0143","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/ol.2023.13747","article-title":"Transporter\u2011mediated drug\u2011drug interactions involving poly (ADP\u2011ribose) polymerase inhibitors (Review)","volume":"25","author":"Zhao","year":"2023","journal-title":"Oncol. Lett."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T10:16:09Z","timestamp":1757844969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":143,"alternative-id":["S0928098725001927"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107193","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107193"}}